Literature DB >> 26599163

PDL-1/PDL-2 blockade in mice dendritic cells by RNAi techniques to induce antitumor immunity.

Saeed Daneshmandi1, Ali Akbar Pourfathollah1, Mohammad Hossein Karimi2, Modjtaba Emadi-Baygi3,4.   

Abstract

AIM: We provided potent dendritic cells (DCs) for induction of stronger antitumor immune responses. MATERIALS &
METHODS: Using siRNA and shRNA systems, PDL-1 and PDL-2 were knocked down and then DC in vitro and in vivo properties were evaluated.
RESULTS: Mild suppression of PDL-1/PDL-2 molecules was accompanied by appropriate expression of DCs co-stimulatory molecules and release of proinflammatory cytokines. In vitro T-cell engagement induced the proliferation and secretion of Th1 cytokines. Injection of DCs to a 4T1 mice model induced intratumor CD8(+) infiltrating lymphocytes, splenocytes expansion, Th1 cytokine profile shift, and a mild drift to tumor growth inhibition and mice survival.
CONCLUSION: Manipulated DCs induced significant antitumor immunity, but this subject needs further evaluation in different animals.

Entities:  

Keywords:  PDL-1; PDL-2; dendritic cell; shRNA; siRNA

Mesh:

Substances:

Year:  2015        PMID: 26599163     DOI: 10.2217/imt.15.80

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  5 in total

1.  Macrophage Gal/GalNAc lectin 2 (MGL2)+ peritoneal antigen presenting cells during Fasciola hepatica infection are essential for regulatory T cell induction.

Authors:  Monique Costa; Valeria da Costa; Pablo Lores; Mercedes Landeira; Santiago A Rodríguez-Zraquia; María Florencia Festari; Teresa Freire
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

Review 2.  Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.

Authors:  Maarten Versteven; Johan M J Van den Bergh; Elly Marcq; Evelien L J Smits; Viggo F I Van Tendeloo; Willemijn Hobo; Eva Lion
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

3.  Fasciola hepatica Immune Regulates CD11c+ Cells by Interacting with the Macrophage Gal/GalNAc Lectin.

Authors:  Ernesto Rodríguez; Paula Carasi; Sofía Frigerio; Valeria da Costa; Sandra van Vliet; Verónica Noya; Natalie Brossard; Yvette van Kooyk; Juan J García-Vallejo; Teresa Freire
Journal:  Front Immunol       Date:  2017-03-15       Impact factor: 7.561

Review 4.  Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy.

Authors:  Mandy van Gulijk; Floris Dammeijer; Joachim G J V Aerts; Heleen Vroman
Journal:  Front Immunol       Date:  2018-12-05       Impact factor: 7.561

Review 5.  Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.

Authors:  Tianyu Tang; Xing Huang; Gang Zhang; Zhengtao Hong; Xueli Bai; Tingbo Liang
Journal:  Signal Transduct Target Ther       Date:  2021-02-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.